What is HC Wainwright’s Estimate for VYGR FY2024 Earnings?

Voyager Therapeutics, Inc. (NASDAQ:VYGR) – Research analysts at HC Wainwright raised their FY2024 EPS estimates for Voyager Therapeutics in a report issued on Wednesday, November 13th. HC Wainwright analyst P. Trucchio now forecasts that the company will post earnings of ($0.82) per share for the year, up from their previous estimate of ($0.97). HC Wainwright has a “Buy” rating and a $30.00 price target on the stock. The consensus estimate for Voyager Therapeutics’ current full-year earnings is ($1.12) per share. HC Wainwright also issued estimates for Voyager Therapeutics’ Q2 2025 earnings at ($0.31) EPS, FY2026 earnings at ($1.38) EPS, FY2027 earnings at ($1.32) EPS and FY2028 earnings at ($1.69) EPS.

VYGR has been the subject of a number of other research reports. Leerink Partnrs raised shares of Voyager Therapeutics to a “strong-buy” rating in a research note on Wednesday, October 16th. Wedbush cut their price target on shares of Voyager Therapeutics from $8.00 to $7.00 and set a “neutral” rating for the company in a research report on Wednesday, August 7th. Leerink Partners assumed coverage on Voyager Therapeutics in a report on Wednesday, October 16th. They issued an “outperform” rating and a $15.00 price objective on the stock. StockNews.com upgraded Voyager Therapeutics from a “hold” rating to a “buy” rating in a report on Monday. Finally, Canaccord Genuity Group reaffirmed a “buy” rating and issued a $14.00 price target on shares of Voyager Therapeutics in a research note on Thursday, November 14th. One investment analyst has rated the stock with a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus target price of $17.00.

Voyager Therapeutics Price Performance

Shares of NASDAQ VYGR opened at $5.27 on Monday. The stock has a market capitalization of $287.90 million, a P/E ratio of 7.42 and a beta of 0.89. Voyager Therapeutics has a one year low of $5.19 and a one year high of $11.72. The firm’s 50 day simple moving average is $6.59 and its two-hundred day simple moving average is $7.45.

Voyager Therapeutics (NASDAQ:VYGR) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($0.16) EPS for the quarter, beating the consensus estimate of ($0.45) by $0.29. The firm had revenue of $24.63 million for the quarter, compared to analyst estimates of $12.63 million. Voyager Therapeutics had a return on equity of 8.33% and a net margin of 15.80%. During the same period in the prior year, the company earned ($0.59) EPS.

Institutional Investors Weigh In On Voyager Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of the stock. Ameritas Investment Partners Inc. raised its stake in Voyager Therapeutics by 49.6% in the first quarter. Ameritas Investment Partners Inc. now owns 3,923 shares of the company’s stock worth $37,000 after buying an additional 1,300 shares in the last quarter. Victory Capital Management Inc. lifted its stake in shares of Voyager Therapeutics by 14.5% in the 2nd quarter. Victory Capital Management Inc. now owns 12,892 shares of the company’s stock valued at $102,000 after purchasing an additional 1,630 shares during the period. SummerHaven Investment Management LLC boosted its position in shares of Voyager Therapeutics by 2.5% during the second quarter. SummerHaven Investment Management LLC now owns 77,293 shares of the company’s stock valued at $611,000 after purchasing an additional 1,921 shares in the last quarter. Hunter Perkins Capital Management LLC grew its stake in Voyager Therapeutics by 3.3% in the third quarter. Hunter Perkins Capital Management LLC now owns 64,040 shares of the company’s stock worth $375,000 after purchasing an additional 2,025 shares during the period. Finally, Empowered Funds LLC raised its holdings in Voyager Therapeutics by 5.4% in the third quarter. Empowered Funds LLC now owns 44,809 shares of the company’s stock worth $262,000 after purchasing an additional 2,278 shares in the last quarter. 48.03% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Voyager Therapeutics

In other Voyager Therapeutics news, insider Sandell Jacquelyn Fahey sold 5,999 shares of the business’s stock in a transaction on Wednesday, October 2nd. The shares were sold at an average price of $5.82, for a total transaction of $34,914.18. Following the transaction, the insider now directly owns 86,001 shares of the company’s stock, valued at approximately $500,525.82. The trade was a 6.52 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 4.53% of the stock is currently owned by corporate insiders.

Voyager Therapeutics Company Profile

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.